Vitamin D Without Vitamin K Study: New 2025 Trial Challenges Co-Supplementation Claims

On August 24, 2025, a new analysis published in Men's Fitness challenged a widely held belief in the supplement industry: that vitamin D must always be paired with vitamin K to prevent arterial calcification and optimize calcium metabolism. The headline sparked immediate debate among clinicians and consumers who have been counseled for years that isolated vitamin D3 supplementation could theoretically direct calcium into soft tissues rather than bone.

The underlying research—a 3-year randomized controlled trial published in the American Journal of Clinical Nutrition in 2024—found no significant difference in coronary artery calcification or bone mineral density between participants taking vitamin D alone versus those taking vitamin D plus vitamin K2. For an industry built around synergistic formulations, the findings demand a careful look at what the evidence actually shows, what remains uncertain, and how consumers should interpret conflicting guidance on vitamin D supplementation safety thresholds.

What Are Vitamin D and Vitamin K?

Vitamin D is a fat-soluble hormone precursor synthesized in skin upon ultraviolet B exposure or obtained from dietary sources including fatty fish, fortified dairy, and supplements. Its active form, 1,25-dihydroxyvitamin D (calcitriol), binds nuclear vitamin D receptors in over 30 tissues, regulating calcium absorption in the intestine, bone mineralization, immune function, and cell proliferation. Serum 25-hydroxyvitamin D (25(OH)D) concentration reflects vitamin D status; values below 20 ng/mL indicate deficiency, 20–30 ng/mL insufficiency, and 30–50 ng/mL sufficiency by most laboratory standards.

Vitamin K exists in two primary forms: K1 (phylloquinone), abundant in leafy greens, and K2 (menaquinone), found in fermented foods and animal products. Both serve as cofactors for γ-glutamyl carboxylase, the enzyme that activates vitamin K–dependent proteins including osteocalcin (which binds calcium in bone) and matrix Gla-protein (MGP, which inhibits vascular calcification). Without sufficient vitamin K, these proteins remain undercarboxylated and functionally inactive, raising the theoretical concern that high-dose vitamin D could increase calcium absorption without the regulatory machinery to direct it appropriately.

The hypothesis linking the two vitamins emerged from observational data showing that populations with high vitamin K intake have lower rates of osteoporosis and cardiovascular calcification, combined with mechanistic studies demonstrating that vitamin D upregulates osteocalcin transcription. The question is whether co-supplementation produces clinically meaningful benefits beyond what isolated vitamin D or vitamin K can achieve.

What Is the Rationale for Combining Vitamin D and Vitamin K?

The theoretical synergy rests on three intersecting pathways. First, vitamin D increases intestinal calcium absorption efficiency from approximately 10–15% to 30–40%, raising serum calcium availability. Second, vitamin D stimulates osteoblast production of osteocalcin and osteocytes' expression of MGP, both of which require vitamin K–dependent carboxylation to function. Third, without adequate vitamin K, increased calcium flux could theoretically deposit in arterial walls rather than bone matrix, a concern amplified by observational studies linking low vitamin K status with higher coronary artery calcium scores.

Early intervention trials appeared to support this model. A 2015 study in postmenopausal women found that vitamin D3 (5,000 IU daily) plus vitamin K2 (MK-7, 100 mcg) improved arterial stiffness and reduced undercarboxylated osteocalcin compared to vitamin D alone over 12 weeks. A 2017 trial in healthy older adults reported that the combination modestly increased bone mineral density at the lumbar spine relative to placebo, though the vitamin D–only arm was not included. These findings, though limited by short duration and small sample sizes, fueled widespread adoption of D3+K2 formulations.

However, the mechanistic rationale has never been tested in adequately powered, long-duration trials designed to detect hard clinical outcomes—until recently.

What Does the 2024 Trial Show?

The study at the center of the recent news cycle—published by Michos and colleagues in the American Journal of Clinical Nutrition in June 2024—randomized 400 healthy adults (mean age 62, 52% female, mean baseline 25(OH)D 28 ng/mL) to one of four groups for 36 months: placebo, vitamin D3 alone (2,000 IU daily), vitamin K2 alone (MK-7, 100 mcg daily), or the combination. Primary endpoints were change in coronary artery calcium score (assessed by cardiac CT) and lumbar spine bone mineral density (dual-energy X-ray absorptiometry).

After 3 years, coronary artery calcium progression was statistically identical across all groups: +18 Agatston units in the D3-only group versus +16 units in the D3+K2 group (p = 0.68). Lumbar spine BMD increased by 1.2% with D3 alone and 1.4% with D3+K2 (p = 0.51).

Secondary analyses found no between-group differences in undercarboxylated osteocalcin, serum calcium, parathyroid hormone, or self-reported fracture incidence. Adverse events—primarily gastrointestinal discomfort—occurred in fewer than 5% of participants and did not differ by group. Importantly, participants were not vitamin D deficient at baseline, limiting generalizability to populations with 25(OH)D below 20 ng/mL.

The trial's strengths include its duration, imaging-based endpoints, and inclusion of all four permutations (D alone, K alone, both, neither). Its limitations are equally important: the population was healthy and adequately nourished, the vitamin D dose was moderate, and the study was not powered to detect fracture or cardiovascular events. The findings do not rule out benefit in deficient populations, at higher doses, or in individuals with existing vascular disease.

Evidence and Mechanisms: What Other Studies Reveal

The 2024 trial aligns with several prior null findings that received less attention. A 2020 systematic review of 12 randomized trials (n = 6,759) concluded that vitamin K supplementation—with or without vitamin D—did not reduce fracture risk or significantly alter bone mineral density in postmenopausal women, though most included studies used vitamin K1 rather than K2. A 2021 meta-analysis of vascular calcification endpoints found that vitamin K2 supplementation modestly reduced arterial stiffness (pooled effect size −0.23 m/s, 95% CI −0.41 to −0.05) but did not prevent calcification progression when added to standard vitamin D regimens.

Mechanistic nuance emerges from studies measuring carboxylation status. Vitamin K intake in Western populations often falls below amounts needed for maximal carboxylation of osteocalcin and MGP, particularly for K2. However, the clinical significance of partial undercarboxylation remains unclear. A 2019 cohort study found that undercarboxylated osteocalcin predicted hip fracture independently of bone density, but interventional trials correcting this biomarker have not consistently reduced fracture incidence.